Merus N.V.

NasdaqGM:MRUS Lagerbericht

Marktkapitalisierung: US$2.9b

Merus Management

Management Kriterienprüfungen 4/4

Merus CEO ist Bill Lundberg , ernannt in Dec 2019, hat eine Amtszeit von 4.92 Jahren. Die jährliche Gesamtvergütung beträgt $4.67M , bestehend aus 13.9% Gehalt und 86.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.22% der Aktien des Unternehmens, im Wert von $6.53M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 6.3 Jahre.

Wichtige Informationen

Bill Lundberg

Geschäftsführender

US$4.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts13.9%
Amtszeit als Geschäftsführer4.9yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.3yrs

Jüngste Management Updates

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 05

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12
Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

May 10
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 01
Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Jan 23

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Jan 14
Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20
Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08
Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14
Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03
New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25
We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28
Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bill Lundberg im Vergleich zu den Einnahmen von Merus verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$245m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$150m

Dec 31 2023US$5mUS$650k

-US$155m

Sep 30 2023n/an/a

-US$177m

Jun 30 2023n/an/a

-US$178m

Mar 31 2023n/an/a

-US$152m

Dec 31 2022US$6mUS$599k

-US$131m

Sep 30 2022n/an/a

-US$64m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$8mUS$582k

-US$67m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$5mUS$565k

-US$86m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$65m

Dec 31 2019US$162kn/a

-US$55m

Vergütung im Vergleich zum Markt: BillDie Gesamtvergütung ($USD4.67M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD6.60M).

Entschädigung vs. Einkommen: BillDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Bill Lundberg (61 yo)

4.9yrs

Amtszeit

US$4,671,327

Vergütung

Dr. Sven Ante Lundberg, also known as Bill, M.D. is Venture Advisor of Forge Life Science Partners. He serves as Chief Executive Officer, President and Executive Director of Merus N.V. since December 31, 2...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Sven Lundberg
CEO, President & Executive Director4.9yrsUS$4.67m0.22%
$ 6.5m
Gregory Perry
Chief Financial Officer1.4yrsUS$6.21m0%
$ 0
Peter Silverman
EVP, Company Secretary6.8yrsUS$1.95mkeine Daten
Hennie Hoogenboom
Co-Founder and Scientific Advisorno datakeine Datenkeine Daten
Harry Shuman
Chief Accounting Officerno datakeine Daten0.010%
$ 300.7k
Cornelis de Kruif
CTO & Executive VP11.8yrsUS$609.22kkeine Daten
Cecilia Anna Geuijen
Chief Scientific Officer & Senior VP3.5yrskeine Datenkeine Daten
Kathleen Farren
IR & Corporate Communications Officerno datakeine Datenkeine Daten
Audrey Bergan
Chief People Officerno datakeine Datenkeine Daten
Shannon Campbell
Executive VP & Chief Commercial Officer2.8yrskeine Datenkeine Daten
Ashley Pereira
Senior Vice President of Regulatory Affairs2.8yrskeine Datenkeine Daten
Ernesto Wasserman
Senior Vice President of Clinical Development2.8yrskeine Datenkeine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: MRUSDas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Sven Lundberg
CEO, President & Executive Director5.4yrsUS$4.67m0.22%
$ 6.5m
Elaine Jones
Board Observer14.8yrskeine Datenkeine Daten
Maxine Gowen
Independent Non-Executive Director3.5yrsUS$305.06k0%
$ 0
Anand Mehra
Independent Chairman9.3yrsUS$417.56k0%
$ 0
Paolo Pucci
Independent Non-Executive Director4.4yrsUS$309.56k0%
$ 0
Mark Iwicki
Independent Non Executive Director9.4yrsUS$311.06k0.11%
$ 3.2m
Antoni Ribas
Member of Scientific Advisory Board6.3yrskeine Datenkeine Daten
Victor Sandor
Independent Non-Executive Director5.4yrsUS$303.56k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board6.3yrskeine Datenkeine Daten
Antonius Schumacher
Member of Scientific Advisory Board6.3yrskeine Datenkeine Daten
Jason Haddock
Independent Non-Executive Directorless than a yearkeine Datenkeine Daten
Len Kanavy
Independent Non-Executive Director6.3yrsUS$303.56k0%
$ 0

6.3yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrener Vorstand: MRUSDie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).